%PDF-1.4
%
1 0 obj
<>stream
iText 4.2.0 by 1T3XT2019-09-25T17:20:54+05:30Arbortext Advanced Print Publisher2019-09-26T06:26:22-07:002019-09-26T06:26:22-07:00uuid:8addd02c-2a8d-4824-a074-0375b52bef83uuid:9735c38c-787b-4f5b-aca7-e8422204bc96JournalLeukemia & Lymphoma© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.1042-81941029-2403001-1011010.1080/10428194.2019.1666381https://doi.org/10.1080/10428194.2019.1666381application/pdf10.1080/10428194.2019.1666381en-USQuality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general populationTaylor & FrancisLeukemia & Lymphoma, 2019. doi: 10.1080/10428194.2019.1666381Ludwig HeinzPönisch WolframKnop StefanEgle AlexanderHinke AxelSchreder MartinLechner DanielHajek RomanGunsilius EberhardPetzer AndreasWeisel KatjaNiederwieser DietgerEinsele HermannWillenbacher WolfgangRumpold HolgerPour LudekJelinek TomasKrenosz Karl JochenMeckl AngelaNolte SandraMelchardt ThomasGreil RichardZojer NiklasMultiple myelomaquality of lifeixazomibthalidomiderelapsed/refractory diseaseVoR2019-09-26truewww.tandfonline.com10.1080/10428194.2019.1666381www.tandfonline.comtrue2019-09-2610.1080/10428194.2019.1666381
endstream
endobj
4 0 obj
<>stream
xZɮ%
ݿ4 Awdax#Q<44JyHQ//f#9.6or}}ÖןFsr6伧}sZ9s:m~}hmiO~ZJK,Ծ{{kZrnCۗ2l??57uB}:|~{{U9fysELA\~s*h
,hz4~G&ٹ~5w&k}~_0kmGSu
˷1Qy'7rAne^}PdQsmUWEt{\_~Ox#VkI#^*Ԏ7c2|%տGUZItZ/kg)ͣOɗ\b3H(nfY(Tʦd`6)PΜ9*h~:di7sd*jI!bW3'U/2"QMK+z5d2m
6Z;'qqF_D6W% !]\t[8|C}Ȍ!ai?P\Tʻ6N+mHN:~tC[B0tO:l5ͅ
w*>@MVGj\*/d$SS*͆Q齺q!R٩K_a
3KU%
]%Wa'G,bVΙAJ/쥈 I1$3TƞԼN%W<Þ0PU!>fy^Xl`ؗS>e]˰jX,1kl/5 F2
FTօjW_D]7ç=8L#ކ]~Ē!'dySjjZdZ$11el5yژ-1˔T r498H)s(WARaTsV53#pڂcXΟ!+MA06@FI`p-#aq3Ǹ,SR1tM
ٻYr%E{{$5aHMdH+Fwkh0 a
-BލNMOAy>бOqꓖ[v=q㻴"ÉTF#lE&=l,v 7Ʃ=ݯç/8:w$w%{R"G |bg}`qD+GHF[؛AfzY
Nhm#u]k :4llJbepiUUvE
7-\+v=t|Ŭ`UT$~V!94=u,kgҘHNk3m]U B>,'6.eFԈ6`~, lot^Y l)zFlْa>$T$.a&z}`~m6HF>{j$KZT&%+|za[t ܙ8U*BY^#>z3Zг\:wDb-6q&䱩"5FCu|oϛ<}z.>̹\Nt݃Cn@"4"'?~
VGlЂH1&{>GaGQ\Eq4#?`pq*I4]H؞ü9$dGS ]ټtDSeI'<)þp;X,z9THbs?؛בS1̭Sg3U"d Z!-jf?QX>V$6Ek?FF,Zz?<BuQWN_).lِ$FL=\/@)eH-2q
c##Hv@}uQ谐2r&t"v>\gDٝ&VA_{m?oh2ZTs+(֣BtOedA W-j@BÙ#* R!+#iIH Ck;턣yIw(~ mgy֫z̢bpqr=4IyhA_
ؖ7X|c=Fo?[yLuǑO4ҁ؛<
'QGAutxR,_M.g>hǃ&wŕzMwn]<ɺL0V&ݏ8&
E81}oizVyN6`c[Lfmx@uBzmTdZX&pw">zH{ q=+I|}-B8BgGȮlJֱM\mL،Kw"?szw[qovr1UwMbJLtLȍUdn ~-q*Ӆ ZzCvo?iM?\V^`}һL%zwlق3fؖM9^FM{
;3UO
c\}(^HL#5[Ŀ4
endstream
endobj
28 0 obj
<>stream
xwXSsN`$!l{@ ٢ $@TR)XZԉ(
RZD|y L0V@(#q `= nnWXX0+Зȕ;ѫ R1{Ol (Lγx\䜙/V'LKP0RX~@9k(8u?̰yBOΑr y
<)_Έ"<?_l)
F+s9H
MI #~__ Q$.R$sŅg%f,a6GTLΟEQԖ!/Bſ)EogEA?l kJ^-ؒ \?l{ P&d\EAt{6~/ÇfJq2bFn6g0<8aO"yD|TyE